Deloitte Recap LLC Free Webinar, Tuesday Morning, Sept. 14, 2010
Topic: “Identify & Mitigate Risks to Avoid Late-Stage Attrition” Date and Time: September 14, 2010, 10:00-11:00 AM Pacific / 1:00-2:00 PM Eastern Cost: Free Register to attend today! Topic Description Why do so many products fail so late in the development process? R&D costs are soaring, regulatory requirements are rising, and comparative effectiveness hurdles loom. Now more than ever, flawed product advancement decisions can take a huge toll on biopharmaceutical companies. The risk of failure should decrease dramatically as drugs advance from Phase I to Phase III trials, yet the evidenc e shows otherwise: high-profile, late-stage product failures remain a core feature of the industry's news cycle. Deloitte Recap data show 30% of products fail in Phase III pivotal trials and 11% fail even later, after a licensure submission has been made. What can the data tell us about why this keeps happening and how to identify and mitigate the risks? Join us on September 14 to explore these questions: • Does the thoroughness, size, and the number of Phase II programs impact success in Phase III? • Have Phase III attrition rates gotten worse over time or remained the same? • Do partnered or in- licensed products fare better or worse? • Are there any "take-home" messages in two decades' worth of drug development decisions? Who should attend: • Business development executives • Portfolio management professionals • Clinical development and regulatory affairs decision makers • CFOs and financial executives Can't attend live? Register to receive the recorded webinar and accompanying slides. Register today!
